The introduction of direct-acting antiviral (DAA) therapies since 2014 has led to an annual decline of about 8.2% in mortality from hepatitis C-related cirrhosis, as highlighted by Dr. Ashraf Ullah and colleagues. An analysis of CDC data showed that while deaths were rising before DAA implementation, they've dropped significantly post-2014. Key findings reveal persistent disparities among populations, with non-Hispanic Black individuals experiencing the steepest decline and ongoing higher rates of mortality noted among men and certain racial groups.

Source: AASLD